Concert Pharmaceuticals has received US patent for CTP-499, its drug candidate being developed for the treatment of diabetic nephropathy.
CTP-499 is a potential treatment developed on the basis of DCE Platform for diabetic nephropathy, a form of chronic kidney disease.
The composition of matter and pharmaceutical compositions of CTP-499, which is at present in Phase 2 clinical testing, are covered in the patent.
Concert senior vice president and general counsel Robert Silverman said the new patent follows patent protection the company received for several of its priority programs.
"We have now used our DCE Platform to make a wide range of substantially differentiated agents which are covered by a worldwide patent estate that includes 26 issued U.S. patents," Silverman added.
Deuterium was incorporated at select positions of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX) in the DCE Platform, which improves the metabolism profile of HDX.
